Mallette Jordan H, Crudup Breland F, Alexander Barbara T
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS USA.
Curr Opin Physiol. 2023 Apr;32. doi: 10.1016/j.cophys.2023.100647. Epub 2023 Feb 13.
Preeclampsia remains a major health concern for mother and child. Yet, treatment options remain limited to early delivery. Placental dysfunction in preeclampsia occurs in response to an increase in oxidative stress and inflammatory cytokines with vasoactive and anti-angiogenic factors contributing to impaired maternal and fetal health. Moreover, recent studies indicate a potential role for epigenetic mediators in the pathophysiology of placental ischemia. Numerous animal models are utilized to explore the pathogenesis of preeclampsia and fetal growth restriction. This review provides a brief overview of recent progress in preclinical studies regarding potential therapeutic targets for the treatment and prevention of preeclampsia with an emphasis on fetal growth restriction and the fetal programming of increased cardiovascular risk.
子痫前期仍然是母婴健康的主要关注点。然而，治疗选择仍然局限于尽早分娩。子痫前期的胎盘功能障碍是对氧化应激和炎性细胞因子增加的反应，血管活性因子和抗血管生成因子会损害母婴健康。此外，最近的研究表明表观遗传介质在胎盘缺血的病理生理学中可能发挥作用。众多动物模型被用于探索子痫前期和胎儿生长受限的发病机制。本综述简要概述了临床前研究在治疗和预防子痫前期潜在治疗靶点方面的最新进展，重点关注胎儿生长受限以及心血管疾病风险增加的胎儿编程。
